For example, studies in patients with NSCLC have shown that higher cGAS expression may predict poorer efficacy of PD-1/PD-L1 inhibitors, even when PD-L1 expression is high, which is probably related to the immunosuppressive effect of TGF-β [139]. The gene discussed is TGFB1; the disease is non-small cell lung carcinoma.